ProteinQure Inc.

ProteinQure is a clinical-stage biotechnology company that specializes in the computational design of exotic, therapeutic peptides. At the center of its operations is ProteinStudio, a proprietary platform that integrates machine learning, molecular simulations, and custom-trained AI models on petascale supercomputers. This platform allows the company to explore vast chemical spaces, incorporating thousands of non-natural amino acids to create peptide-drug conjugates. These conjugates are engineered for precise, tissue-specific delivery of therapeutic payloads, offering advantages over traditional antibody-drug conjugates, such as improved pharmacokinetics, deeper tissue penetration, and lower immunogenicity.

The company's lead program, PQ203, is a peptide-drug conjugate currently in Phase 1 clinical trials for advanced solid tumors, including triple-negative breast cancer. By utilizing structure-based drug design and in-house wetlab validation, ProteinQure aims to address unmet medical needs in oncology and beyond, with additional research programs targeting renal biology and the blood-brain barrier. The company serves the pharmaceutical industry through internal pipeline development and external collaborations, effectively bridging the gap between computational discovery and clinical-stage precision medicine.